Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia

National Cancer I, 2016 Juliusson, 2012, Swedish Acute Leukemia Registry G. Acute myeloid leukemia in the real world: why population-based registries are needed, Blood, 119, 3890, 10.1182/blood-2011-12-379008 Koreth, 2009, Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: a systematic review and meta-analysis of prospective clinical trials, J Am Med Assoc, 301, 2349, 10.1001/jama.2009.813 Dohner, 2017, Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, 129, 424, 10.1182/blood-2016-08-733196 McClune, 2010, Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome, J Clin Oncol, 28, 1878, 10.1200/JCO.2009.25.4821 Sorror, 2017, Allogeneic hematopoietic cell transplantation (HCT) in the eighth decade of life: how much does age matter?, Biol Blood Marrow Transplant, 23, S98, 10.1016/j.bbmt.2017.01.040 Farag, 2011, Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission, Biol Blood Marrow Transplant, 17, 1796, 10.1016/j.bbmt.2011.06.005 Medeiros, 2015, Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States, Ann Hematol, 94, 1127, 10.1007/s00277-015-2351-x Sorror, 2007, Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences, Blood, 110, 4608, 10.1182/blood-2007-06-096966 Sorror, 2017, Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality, JAMA Oncol, 10.1001/jamaoncol.2017.2714 Mawad, 2013, Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission, J Clin Oncol, 31, 3883, 10.1200/JCO.2013.50.2567 Fenaux, 2010, Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia, J Clin Oncol, 28, 562, 10.1200/JCO.2009.23.8329 Dombret, 2015, International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts, Blood, 126, 291, 10.1182/blood-2015-01-621664 Walter, 2015, Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation, Leukemia, 29, 137, 10.1038/leu.2014.173 Araki, 2016, Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission?, J Clin Oncol, 34, 329, 10.1200/JCO.2015.63.3826 Yezefski, 2016, Rates of CR with and without measurable residual disease after induction treatment with “7+3” or azacitidine/decitabine for newly-diagnosed AML, 128 Walter, 2011, Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment, J Clin Oncol, 29, 4417, 10.1200/JCO.2011.35.7525 Sorror, 2016, Intensive versus non-intensive induction therapy for patients (Pts) with newly diagnosed acute myeloid leukemia (AML) using two different novel prognostic mode, 128